S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes

Cell Calcium

Volumn 41, Issue 2, 2007, Pages 135-143

  Völkers, Mirko ^a   Loughrey, Christopher M ^b   MacQuaide, Niall ^b   Remppis, Andrew ^a   DeGeorge Jr , Brent R ^c   Wegner, Frederic v ^a   Friedrich, Oliver ^a   Fink, Rainer H A ^a   Koch, Walter J ^c   Smith, Godfrey L ^b   Most, Patrick ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c George Zallie and Family Laboratory for Cardiovascular Gene Therapy   (United States)

Author keywords

Calcium; Ryanodine receptor; S100A1; Sparks

Indexed keywords

CALCIUM ION; PROTEIN S 100; PROTEIN S 100A1; RYANODINE RECEPTOR 2; SORCIN; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE PERMEABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLE; FREQUENCY ANALYSIS; HEART MUSCLE CELL; INOTROPISM; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RABBIT; SARCOPLASMIC RETICULUM; STOICHIOMETRY;

ORYCTOLAGUS CUNICULUS;

EID: 33845891118     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2006.06.001     Document Type: Article

References (34)

1. Haimoto H., and Kato K. S100a0 (alpha alpha) protein in cardiac muscle. Isolation from human cardiac muscle and ultrastructural localization. Eur. J. Biochem. 171 (1988) 409-415
2. Kato K., and Kimura S. S100ao (alpha alpha) protein is mainly located in the heart and striated muscles. Biochim. Biophys. Acta 842 (1985) 146-150
3. Kiewitz R., Lyons G.E., Schafer B.W., and Heizmann C.W. Transcriptional regulation of S100A1 and expression during mouse heart development. Biochim. Biophys. Acta 1498 (2000) 207-219
4. Kettlewell S., Most P., Currie S., Koch H., and Smith G.L. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39 (2005) 900-910
5. 2+-cycling in ventricular rat cardiomyocytes. J. Cell Sci. 118 (2005) 421-431
6. Most P., Pleger S.T., Völkers M., Heidt B., Boerries M., Weichenhan D., Löffler E., Janssen P.M., Eckhart A.D., Martini J., Williams M.L., Katus H., Remppis A., and Koch W.J. Cardiac adenoviral S100A1 gene transfer rescues failing myocardium. J. Clin. Invest. 114 (2004) 1550-1563
7. 2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J. Biol. Chem. 278 (2003) 33809-33817
8. 2+ release channel (ryanodine receptor) of skeletal muscle. Biochemistry 36 (1997) 11496-11503
9. 2+ release from isolated sarcoplasmic reticulum vesicles. FEBS Lett. 255 (1989) 381-384
10. 2+ release in murine skinned skeletal muscle fibres. J. Biol. Chem. 278 (2003) 26356-26364
11. Most P., Boerries M., Eicher C., Schweda C., Ehlermann P., Pleger S.T., Löffler E., Koch W.J., Katus H.A., Schoenenberger C.A., and Remppis A. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular-regulated kinase (ERK1/2) pathway. J. Biol. Chem. 278 (2003) 48404-48412
12. 2+ cycling in rat cardiac myocytes. Basic. Res. Cardiol. 97 (2002) I/56-I/62
13. Loughrey C.M., Seidler T., Miller S.L.W., Prestle J., MacEachern K.E., Reynolds D.F., Hasenfuss G., and Smith G.L. Overexpression of FK506-binding protein FKPB12.6 alters excitation-contraction coupling in adult rabbit cardiomyocytes. J. Physiol. 556 3 (2004) 919-934
14. Cheng H., Song L.S., Shirokova N., Gonzalez A., Lakatta E.G., Rios E., and Stern M.D. Amplitude distribution of calcium sparks in confocal images: theory and studies with an automatic detection method. Biophys. J. 76 (1999) 606-617
15. Wehrens X.H., Lehnart S.E., Huang F., Vest J.A., Reiken S.R., Mohler P.J., Sun J., Guatimosim S., Song L.S., Rosemblit N., D'Armiento J.M., Napolitano C., Memmi M., Priori S.G., Lederer W.J., and Marks A.R. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 113 (2003) 829-840
16. Groves P., Finn B.E., Kuznicki J., and Forsen S. A model for target protein binding to calcium-activated S100 dimers. FEBS Lett. 421 (1998) 175-179
17. Osterloh D., Ivanenkov V.V., and Gerke V. Hydrophobic residues in the C-terminal region of S100A1 are essential for target protein binding but not for dimerization. Cell Calcium 24 (1998) 137-151
18. 2+-binding protein human S100A1. Acta Crystallogr. D. Biol. Crystallogr. 57 (2001) 882-883
19. 2+-bound S100A1 as determined by NMR Spectroscopy. J. Mol. Biol. 353 (2005) 410-426
20. Zimmer D.B., Wright S.P., and Weber D.J. Molecular mechanisms of S100-target protein interactions. Microsc. Res. Tech. 60 (2003) 552-559
21. Diaz M.E., Graham H.K., O'Neill S.C., Trafford A.W., and Eisner D.A. The control of sarcoplasmic reticulum Ca content in cardiac muscle. Cell Calcium 38 (2005) 391-396
22. Hamilton S.L. Ryanodine receptors. Cell Calcium 38 (2005) 253-260
23. Wehrens X.H., and Marks A.R. Molecular determinants of altered contractility in heart failure. Ann. Med. 36 Suppl. 1 (2004) 70-80
24. Bers D.M. Macromolecular complexes regulating cardiac ryanodine receptor function. J. Mol. Cell Cardiol. 37 (2004) 417-429
25. 2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Trends Pharmacol. Sci. 19 (1998) 479-482
26. Baudier J., and Gerard D. Ions binding to S100 proteins. II. Conformational studies and calcium-induced conformational changes in S100 alpha alpha protein: the effect of acidic pH and calcium incubation on subunit exchange in S100a (alpha beta) protein. J. Biol. Chem. 261 (1986) 8204-8212
27. 2+ binding on S100b protein. J. Biol. Chem. 261 (1986) 8192-8203
28. 2+)-binding protein family. Biometals 11 (1998) 383-397
29. Most P., Bernotat J., Ehlermann P., Pleger S.T., Reppel M., Borries M., Niroomand F., Pieske B., Janssen P.M., Eschenhagen T., Karczewski P., Smith G.L., Koch W.J., Katus H.A., and Remppis A. S100A1: a regulator of myocardial contractility. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13889-13894
30. Okada M., Hatakeyama T., Itoh H., Tokuta N., Tokumitsu H., and Kobayashi R. S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex. J. Biol. Chem. 279 (2004) 4221-4233
31. Pleger S.T., Remppis A., Heidt B., Völkers M., Chaprun J.K., Kuhn M., Zhou R.H., Gao E., Szabo G., Weichenhan D., Müller O.J., Eckhart A.D., Katus H.A., Koch W.J., and Most P. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol. Ther. 12 (2005) 1120-1129
32. 2+)-binding protein S100A1 in human cardiomyopathy. Biochim. Biophys. Acta 1313 (1996) 253-257
33. Most P., and Koch W.J. Sealing the leak, healing the heart. Nat. Med. 9 (2003) 993-994
34. P. Most, H. Seiffert, E.G. Gao, H. Funakoshi, M. Völkers, J. Heierhorst, A. Remppis, S.T. Pleger, B. DeGeorge, A.D. Eckhart, A.M. Feldman, W.J. Koch, Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction, Circulation, 2006, in press.